Last reviewed · How we verify
Onexton™ Gel
Onexton is a topical combination gel containing clindamycin and benzoyl peroxide that reduces acne by killing bacteria and decreasing sebum production.
Onexton is a topical combination gel containing clindamycin and benzoyl peroxide that reduces acne by killing bacteria and decreasing sebum production. Used for Acne vulgaris.
At a glance
| Generic name | Onexton™ Gel |
|---|---|
| Also known as | Clindamycin, BPO, Clindamycin/benzoyl peroxide gel |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Topical antibiotic combination |
| Target | Bacterial ribosome (clindamycin); oxidative mechanism (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, targeting Cutibacterium acnes (formerly Propionibacterium acnes). Benzoyl peroxide acts as an oxidizing agent that kills bacteria and helps prevent antibiotic resistance. Together, they provide synergistic antimicrobial and anti-inflammatory effects on acne lesions.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Erythema
- Dryness
- Peeling
Key clinical trials
- A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris (PHASE1)
- Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications (PHASE4)
- A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris (PHASE3)
- A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Onexton™ Gel CI brief — competitive landscape report
- Onexton™ Gel updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI